


PHARMACEUTICAL 2019



Aquestive Therapeutics Inc. Rank 249 of 371





PHARMACEUTICAL 2019



Aquestive Therapeutics Inc. Rank 249 of 371

The relative strengths and weaknesses of Aquestive Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aquestive Therapeutics Inc. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 193% points. The greatest weakness of Aquestive Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 163% points.

The company's Economic Capital Ratio, given in the ranking table, is -291%, being 40% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	74,201
Cost of Goods Sold	0
Intangible Assets	204
Liabilities, Current	32,952
Liabilities, Non-Current	0
Other Assets	239
Other Compr. Net Income	0
Other Expenses	33,982
Other Liabilities	43,819
Other Net Income	0
Property and Equipment	12,207
Research and Development	23,112
Revenues	67,982
Selling, General and Administrative Expense	72,264

Output Variable	Value in 1000 USD
Assets	86,851
Liabilities	76,771
Expenses	129,358
Stockholders Equity	10,080
Net Income	-61,376
Comprehensive Net Income	-61,376
Economic Capital Ratio	-291%